TY - JOUR
T1 - Histone deacetylase inhibitor-induced sensitization to TNFα/TRAIL- mediated apoptosis in cervical carcinoma cells is dependent on HPV oncogene expression
AU - Darvas, Katalin
AU - Rosenberger, Simone
AU - Brenner, Dirk
AU - Fritsch, Cornelius
AU - Gmelin, Nadine
AU - Krammer, Peter H.
AU - Rösl, Frank
PY - 2010/9/1
Y1 - 2010/9/1
N2 - Histone-deacetylase (HDAC) inhibitors (HDACi) can block proliferation and induce intrinsic apoptosis in human papillomavirus (HPV)-positive cervical carcinoma cells, independently of copy number and integration locus of the viral DNA. Using HPV18-positive HeLa cells as model systems, we provide evidence that HDAC inhibition leads to transcriptional suppression of c-FLIP, which negatively regulates extrinsic apoptosis by preventing the recruitment of caspase-8 to the death-inducing signaling complex. Consequently, HDACi pretreatment renders cervical cancer cells sensitive to TNFα and TRAIL-induced apoptosis. Already 5-hr incubation with TNFα or TRAIL was sufficient to eradicate more than 40% of pretreated cells, which are normally completely refractory against respective death-ligands alone even under long-term incubation. Ectopic expression of either short or long splicing variant of c-FLIP, c-FLIPs and c-FLIPL, abrogates sensitization. Notably, combined HDACi/death ligand treatment did not result in eradication of HPV-negative cells, despite the fact that both c-FLIP isoforms were also downregulated. However, knocking down HPV18 E6/E7 transcription by siRNA prevents HDACi/death-ligand mediated apoptosis, indicating that continued viral oncogene expression favors sensitization. Here, the viral oncoprotein E7 seems to play a functional role, since only HPV16 E7-immortalized human keratinocytes underwent significant apoptosis on HDACi/TNFα treatment, whereas keratinocytes expressing only HPV16 E6 or primary keratinocytes were refractory under the same experimental conditions. Taken together, HDACi can be considered as an alternative therapeutic option in the treatment of premalignant and malignant lesions.
AB - Histone-deacetylase (HDAC) inhibitors (HDACi) can block proliferation and induce intrinsic apoptosis in human papillomavirus (HPV)-positive cervical carcinoma cells, independently of copy number and integration locus of the viral DNA. Using HPV18-positive HeLa cells as model systems, we provide evidence that HDAC inhibition leads to transcriptional suppression of c-FLIP, which negatively regulates extrinsic apoptosis by preventing the recruitment of caspase-8 to the death-inducing signaling complex. Consequently, HDACi pretreatment renders cervical cancer cells sensitive to TNFα and TRAIL-induced apoptosis. Already 5-hr incubation with TNFα or TRAIL was sufficient to eradicate more than 40% of pretreated cells, which are normally completely refractory against respective death-ligands alone even under long-term incubation. Ectopic expression of either short or long splicing variant of c-FLIP, c-FLIPs and c-FLIPL, abrogates sensitization. Notably, combined HDACi/death ligand treatment did not result in eradication of HPV-negative cells, despite the fact that both c-FLIP isoforms were also downregulated. However, knocking down HPV18 E6/E7 transcription by siRNA prevents HDACi/death-ligand mediated apoptosis, indicating that continued viral oncogene expression favors sensitization. Here, the viral oncoprotein E7 seems to play a functional role, since only HPV16 E7-immortalized human keratinocytes underwent significant apoptosis on HDACi/TNFα treatment, whereas keratinocytes expressing only HPV16 E6 or primary keratinocytes were refractory under the same experimental conditions. Taken together, HDACi can be considered as an alternative therapeutic option in the treatment of premalignant and malignant lesions.
KW - Cervical cancer
KW - E6/E7 viral oncoproteins
KW - Human papillomaviruses
KW - Therapy
KW - c-Flip isoforms
UR - http://www.scopus.com/inward/record.url?scp=77955635418&partnerID=8YFLogxK
U2 - 10.1002/ijc.25170
DO - 10.1002/ijc.25170
M3 - Article
C2 - 20087862
AN - SCOPUS:77955635418
SN - 0020-7136
VL - 127
SP - 1384
EP - 1392
JO - International Journal of Cancer
JF - International Journal of Cancer
IS - 6
ER -